Clinical Data Amgen scores with new thyroid eye disease formulation PharmaphorumCan Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?Clinical DataOphthalmologyRead full story pharminent April 7, 2026 (Last updated: April 8, 2026) Pharmaphorum Can Amgen’s subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster? Clinical DataOphthalmologyRead full story Post navigation Previous: FDA floats new clinical trial reforms; Takeda punts Denali brain drugNext: Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3 Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026